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Abstract
The genetic risk factors predisposing individuals to the development of inflammatory bowel disease are beginning to be
deciphered by genome-wide association studies. Surprisingly, these new data point towards a critical role of autophagy in
the pathogenesis of Crohn’s disease. A single common coding variant in the autophagy protein ATG16L1 predisposes
individuals to the development of Crohn’s disease: while ATG16L1 encoding threonine at amino acid position 300
(ATG16L1*300T) confers protection, ATG16L1 encoding for alanine instead of threonine (ATG16L1*300A, also known as
T300A) mediates risk towards the development of Crohn’s disease. Here we report that, in human epithelial cells, the
Crohn’s disease-associated ATG16L1 coding variant shows impairment in the capture of internalized Salmonella within
autophagosomes. Thus, we propose that the association of ATG16L1*300A with increased risk of Crohn’s disease is due to
impaired bacterial handling and lowered rates of bacterial capture by autophagy.
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Introduction
Crohn’s disease (CD) is a complex, multigenic disease with
several identified genetic and non-genetic risk factors [1–4].
Despite this fundamental complexity, the known risk factors
strongly support a role for the innate, adaptive immune response
and autophagy in CD pathogenesis. Autophagy is a diverse
process, with several forms described to date [5]. However, the
most studied form is ‘‘macroautophagy’’ whereby cellular contents
are encapsulated in double membraned autophagosomes and
delivered to lysosomes, where they are degraded and their
constituents recycled. This macroautophagic process is increased
in times of cellular stress, such as starvation or growth factor
withdrawal, for which the term ‘‘induced autophagy’’ has been
suggested [6]. In addition to basal autophagy, where autophago-
somes form constitutively in a stochastic fashion throughout the
cytoplasm and encapsulate a non-selected cargo, there appear to
be more selective forms of autophagy (typically induced by protein
aggregates and bacterial pathogens) with cargo selection by as yet
unknown signals [7,8]. Autophagy is thought to protect the cell by
eliminating or limiting the growth of bacterial pathogens, a process
termed ‘‘xenophagy’’ [9]; therefore dysfunction of xenophagy
might lead to persistent infection. In the case of Salmonella enterica
subsp. enterica serotype Typhimurium (S. Typhimurium), it has
been shown that xenophagy provides a significant contribution to
pathogen control, and loss of autophagy results in enhanced
bacterial replication within the intracellular niche [8]. Although
the current evidence does not support autophagy as a universal
defense against bacterial infection, the enhanced control of S.
Typhimurium burden mediated by autophagy indicates that it
forms part of the innate defense against Salmonella infection.
Therefore, we shall refer to autophagy of internalized Salmonellae as
anti-Salmonella autophagy.
Recently, a coding polymorphism in the autophagy gene
ATG16L1 was identified as a risk factor for the development of
CD [10,11], and we demonstrated that ATG16L1 is essential for
mammalian autophagy under a variety of induction stimuli,
including Salmonella Typhimurium infection. In this study, we build
upon our previous experiments, directly address the biochemical
properties of ATG16L1 coding variants, and provide the first
evidence that the ATG16L1*300A variant is associated with a loss-
of-function phenotype upon challenge by an intracellular pathogen.
Materials and Methods
Antibodies
Mouse monoclonal antibodies used in this study were anti-
FLAG (M2, Sigma, MO USA), anti-HA (16B12, Covance, NJ
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3391USA), Anti-GFP (B34, Covance) and anti-MYC (9E10, Covance).
Anti-actin and anti-LC3B rabbit polyclonal antibodies were
purchased from Sigma (MO, USA). Detection of beta Galacto-
sidase protein was performed using a rabbit polyclonal antibody
(Abcam, MA USA). In addition, two polyclonal antibodies against
synthetic peptides corresponding to human ATG16L1 were
purchased from Affinity BioReagents (CO USA) and were
prepared by immunization of rabbits and affinity purified
(sequences used for anti-ATG16L1-01 and anti-ATG16L1-02
were EKHDVPNRHEISPGHDGT and AEKAQEANRLNAE-
NEKD, respectively).
Plasmids and RNA interference (RNAi)
Human ATG16L1 isoforms 1 (NM_030803) and 2
(NM_017974) were amplified from cDNAs obtained from
OriGene (MD USA), template cDNA for human ATG5
(NM_004849) was purchased from Open Biosystems (AL USA).
Subsequent cloning of truncated versions of ATG16L1 was
performed by polymerase chain reactions (PCR) using ATG16L1
isoform 1 as DNA template. ATG5 and ATG16L1 cDNAs were
cloned into a modified version of pCMV (Clontech, CA USA)
containing an N-terminal FLAG-, MYC- or HA-tag, as indicated.
Expression plasmids coding for the ATG16L1*300A variant were
generated from their *300T counterparts by site-directed muta-
genesis. Further, site-directed mutagenesis was applied to intro-
duce two silent mutations within the regions of ATG16L1-cDNA,
whose corresponding mRNA regions are targeted by ATG16L1
small interfering RNAs (siRNAs) 1 and 2, respectively. ATG16L1
cDNAs resistant to siRNAs 1 or 2 were used to generate additional
expression constructs by polymerase chain reaction and subse-
quently cloned into pCMV (untagged ATG16L1) or a modified
version of pCMV carrying an in-frame C-terminal FLAG-tag.
SiRNA duplexes were purchased from Invitrogen and have been
previously validated [11], catalogue numbers for each duplex are:
siRNA 1 – HSS147871; siRNA 2 – HSS147872.
To allow for stable suppression of ATG16L1 expression, a short
hairpin RNA (shRNA) construct corresponding to ATG16L1
siRNA 1 was cloned into the unique restriction sites EcoRI and
AgeI of pLKO.1. pLKO.1 cloning vector, pLKO.1 non-targeting
control shRNA-vector, packaging plasmid pCMV-dR8.91 and
envelope plasmid VSV-G/pMD2.G were purchased from the
RNAi Consortium (The Broad Institute, MA USA).
The lentiviral construct, used to generate cell lines stably
expressing GFP-hLC3B, was a kind gift from Dr. C. Mu ¨nz
(Rockefeller University, New York). The expression construct for
beta-Galactosidase was kindly provided by Dr. M. Scheffner
(University of Konstanz, Germany).
Cell culture, transfections and viral infections
HeLa, HEK293, HEK293T and Caco2 cells were cultured in
DMEM (Gibco, CA USA) supplemented with 10% iron-supple-
mented calf serum (CSFe) (Hyclone, UT USA) and 20 mg/ml
gentamycin sulfate. Transfections of HeLa and HEK293 cells were
performed using Lipofectamine 2000 (Invitrogen, CA USA), for
transfections of HEK293T cells TransFectin (BioRad, CA USA)
was used. Transfection of Caco2 cells was performed using an
Amaxa Nucleofector system with Cell Line NucleofectorH Kit T,
program B-24, according to the manufacturer’s instructions
(Amaxa, Germany). GFP-hLC3B- and shRNA-encoding lentiviral
particles,were generated and transduced according to standard
protocols given by the RNAi Consortium (The Broad Institute, MA
USA) with minor modifications. For selection of Caco2 cells stably
expressing control shRNA or shRNA directed against ATG16L1,
respectively,puromycin(Sigma) wasadded tocell culture mediaat a
final concentration of 6 mgm l
21.
Bacterial-autophagy assays
Infections with Salmonella enterica sbsp enterica serotype Typhi-
murium strain SL1344 (S. Typhimurium) carrying a DsRed2
expression plasmid (Clontech) were performed as previously
described [11]. The total number of bacteria per cell, and the
number of GFP-LC3 positive bacteria were assessed in randomly
chosen fields with at least 120 cells counted for each condition.
The numbers of GFP-LC3 positive bacteria were then calculated
as a percentage of total bacteria. Significance was assessed using
the two-tailed, unequal variance Student’s t-test. Representative
images were taken using a Leica SP5 confocal microscope (Leica
Microsystems Inc, IL USA) and are displayed as single optical
sections from high-resolution z-stacks.
Results
Experimental design for coding variant-specific cell
culture assays
We have previously demonstrated that human ATG16L1 is
essential for autophagosome formation in human epithelial cells in
the contexts of both serum withdrawal and bacterial infection [11].
However, the function(s) of ATG16L1 which are affected by the
coding variation remain unknown. To this end, we applied a
knock-down/reconstitution strategy, as previously described [12].
Within this system, expression of endogenous ATG16L1 is
suppressed by means of RNAi, and ATG16L1 expression is
reconstituted via transfection of an expression plasmid in which
the ATG16L1 cDNA contains synonymous mismatches within the
RNAi target sequence, preventing efficient RNAi targeting, but
maintaining amino acid fidelity. Initially, we tested if and to what
extent epitope tags might affect ATG16L1 expression constructs in
their ability to rescue the loss of endogenous ATG16L1
expression. Therefore, we performed reconstitution assays
(knock-down of endogenous ATG16L1 by RNAi and reconstitu-
tion of ATG16L1*300T expression by co-transfection of N-
terminal tagged, C-terminal tagged and untagged, respectively,
ATG16L1 expression plasmids) in cell lines stably expressing the
autophagy marker GFP-LC3. Autophagy levels were determined
via the extent of accumulation of membrane-bound GFP-LC3-II,
serving as a positive marker of autophagosome formation [13],
upon inhibition of lysosomal turnover in the absence of any further
stimuli (basal autophagy). Surprisingly, both FLAG-tagged (N- and
C-terminal, respectively) ATG16L1 expression constructs appear
to be less competent than untagged ATG16L1*300T in their
ability to rescue autophagy to levels seen with endogenous
ATG16L1 (expression of control siRNA along with an empty
expression vector) (Fig. 1). While the extent of reconstitution
efficacy varies between HeLa cells and HEK293 cells, the trend
seen for N-, C- and untagged ATG16L1 is consistent between
both cell lines, suggesting that the placement of epitope tags has
adverse effects upon the autophagy efficacy of ATG16L1
constructs. In summary, we are able to induce and functionally
rescue loss of endogenous ATG16L1 expression using ATG16L1
RNAi-resistant expression constructs carrying no epitope tag.
ATG16L1*300A is defective in mediating efficient anti-
bacterial autophagy in HeLa and Caco2 cells
As the critical CD risk-conferring amino acid position 300 of
ATG16L1 is within a region of mammalian ATG16L1 absent in
yeast ATG16, we hypothesized that the specialized anti-bacterial
from of autophagy would be affected rather than basal forms of
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the high prevalence of the CD risk-conferring ATG16L1*300A
variant in the human population most likely argues against a
general deleterious autophagy phenotype. Thus, we reasoned that
subtle differences in ATG16L1 variant function might be revealed
in Salmonella infection assays [8,11]. Therefore, we applied our
knock-down/reconstitution system, including variant specific
ATG16L1 reconstitution, followed by infection with S. Typhimur-
ium infection and measured the percentage of GFP-LC3 captured
bacteria.
In the presence of endogenous ATG16L1, ATG16L1*300A-
expressing HeLa cells are consistently less able to capture bacteria
within autophagosomes than ATG16L1*300T expressing cells
(Fig. 2A, left panel). Strikingly, in the absence of endogenous
ATG16L1, ATG16L1*300A-expressing cells are markedly less
effective in anti-Salmonella autophagy, recovering less than half of
the activity displayed by the ATG16L1*300T protein (Fig. 2A,
right panel). In addition, in the absence of endogenous ATG16L1
protein, levels of ATG16L1*300A were consistently lower than
ATG16L1*300T after bacterial challenge (data not shown and
Fig. 2B). This effect was not seen without infection and was only
observed in the absence of endogenous ATG16L1 (Fig. 2B). This
suggests that the relative instability of the *300A variant protein
can be largely compensated for by endogenous levels of
ATG16L1*300T, or perhaps suggesting that ATG16L1*300A is
only targeted within a functional ATG5/ATG12/ATG16L1
complex while over-expressed ATG16L1 only inefficiently incor-
porates into pre-existing ATG5/ATG12/ATG16L1 complexes as
suggested by Fujita et al [14].
We confirmed these findings in a human gut epithelial cell line
by establishing a modified knock-down/reconstitution strategy in
CaCo2 cells (Fig. 3A). These cells were lentivirally transduced to
generate a stable knock-down of ATG16L1 protein expression
(Fig. 3A inset) and subsequently nucleofected with ATG16L1
reconstitution constructs and GFP-LC3. The phenotype observed
in Caco2 cells closely mirrored that of our HeLa system. Under
conditions of endogenous ATG16L1 ablation, expression of
ATG16L1*300A failed to fully rescue autophagy of S. Typhimur-
ium, whereas ATG16L1*300T yielded robust anti-Salmonella
autophagy. Representative images of infected Caco2 cells showing
that cells expressing either ATG16L1 variant are able to capture
Salmonella within autophagosomes, albeit at a reduced rate in the
case of ATG16L1*300A, are shown in Figure 3B.
Taken together, these findings demonstrate that the CD-
associated variant ATG16L1*300A is less able to mediate anti-
Salmonella autophagy. We proposed that the underlying mecha-
nism might be related to an impaired ability of the *300A variant
to interact with other proteins within the autophagic complex.
The ATG16L1*300A variant exhibits no defect in
dimerisation or binding to ATG5
Since yeast and murine ATG16(L1) proteins have the capacity
to build homodimers mediated by their coiled-coil domain and are
able to interact with ATG5 depending on their very N-terminus
[15–17], it was tempting to speculate that corresponding domains
of human ATG16L1 will act in the same manner within the
human autophagy system. To address this issue, in addition to our
ATG16L1 isoform 1 constructs (ATG16L1*300T and *300A), we
constructed a panel of expression constructs reflecting ATG16L1
isoform 2, and three truncated forms of ATG16L1*300T (Fig. 4A).
The ATG16L1 isoform 2 lacks a single exon of unknown function
between the coiled-coil domain and the WD repeats. The
construct DN lacks the N-terminal domain, but retains all other
features of isoform 1. Since the WD repeat region is entirely absent
from the yeast ATG16 homologue, two synthetic truncations were
made, either lacking all WD repeats (DWD), or consisting of solely
the WD repeats, plus a small undefined region distal to the coiled-
coil (WD).
We investigated which of these constructs were able to co-
precipitate human ATG16L1 isoform 1 and human ATG5 using
over-expression of N-terminal tagged constructs in HEK293T cells
followed by co-immunoprecipitation assays. We used tagged
constructs, since this was the only way to immunoprecipitate all
truncated versions and to distinguish ATG16L1*300T and *300A.
In addition, recent data demonstrate that an inhibitory effect of N-
terminal tagged ATG16L1 can be overcome by over-expression of
ATG5 and ATG12 [14]. This suggests that excess levels of
ATG16L1 are the cause of inhibition, but the biochemical
Figure 1. Differentially tagged ATG16L1*300T constructs show differential abilities to mediate basal autophagy. In a 12-well format,
HeLa and HEK293 cells, stably transduced to express GFP-LC3, were co-transfected with control siRNA and empty FLAG-vector or ATG16L1 siRNA and
empty FLAG-vector or expression constructs encoding ATG16L1 carrying no tag (‘ATG16L1’) a 3-fold FLAG-tag at its N-terminus (‘
FLAGATG16L1’) or C-
terminus (‘ATG16L1
FLAG’), as indicated. 48 h. post-transfection, 50 mM ammonium chloride (NH4Cl) was added for 2 h., where indicated, to block
lysosomal turnover of GFP-LC3. Protein levels of GFP-LC3-I (cytosolic) and GFP-LC3-II (membrane-bound) were determined by Western blot analysis
using anti-GFP-antibody.
doi:10.1371/journal.pone.0003391.g001
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that N-terminal tagged ATG16L1 expression constructs are
suitable for biochemical studies such as co-immunoprecipitation
assays, yet functional assays are likely to be more reliable using
ATG16L1 constructs carrying no epitope tag.
First, MYC-tagged ATG16L1*300T-isoform 1 or HA-tagged
ATG5 were co-expressed with FLAG-tagged versions of each of the
described ATG16L1*300T constructs. Immunoprecipitation was
performed using anti-FLAG antibody and co-precipitated proteins
were detected by Western blotting using a MYC-specific antibody
(for ATG16L1 isoform 1) or HA-specific antibody (for ATG5).
Using this technique, we were able to demonstrate that human
ATG16L1 requires a region between amino acids 85 through 285
to interact with other ATG16L1 moieties, most likely reflecting
self-dimerisation mediated by the coiled-coil domain (Fig. 4B).
Notably, the WD domains of human ATG16L1, which are absent
in yeast ATG16, failed to co-immunoprecipitate ATG16L1. In
addition, ATG16L1 interacts with ATG5 via the N-terminal
domain of ATG16L1 (Fig. 4C), as no binding of ATG5 was
observed for any of the ATG16L1 constructs missing the N-
terminal 84 amino acids. Additionally, in the absence of exogenous
ATG16L1 binding, the level of ATG5 protein was markedly
Figure 2. ATG16L1*300T is defective in mediating anti-Salmonella autophagy in HeLa cells. (A) HeLa cells stably expressing GFP-LC3 were
co-transfected with control or ATG16L1-targeting siRNA and empty vector, ATG16L1*300T or ATG16L1*300A expression constructs, as indicated.
48 h. following transfection, cells were infected with S. Typhimurium (SL1344) for 1 h. and fixed. The percentage of internalized bacteria captured
within GFP-LC3-positive autophagosomes was calculated and is shown as means with error bars representing standard errors. P values were
calculated as described in Material and Methods. (B) HeLa cells were co-transfected as described in Fig. 2A with the additional co-transfection of a
beta-galactosidase expression plasmid in each sample. 48 h. following transfection, one set of cells was left untreated (w/o infection) while the other
set was infected with S. Typhimurium (SL1344) for 1 h. 5% of each lysate were used for straight Western blotting and detection of beta-galactosidase
(b-Gal) (indicator of transfection efficiency) and actin (loading control). ATG16L1 expression levels were detected in the remaining 95% of each lysate
by immunoprecipitation with anti-ATG16L1-02 antibody and Western blot analysis using anti-ATG16L1-01 antibody. Note the loss of ATG16L1*300A
protein (compared to *300T and without infection) during S. Typhimurium infection – arrowed. w/o, without.
doi:10.1371/journal.pone.0003391.g002
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PLoS ONE | www.plosone.org 4 October 2008 | Volume 3 | Issue 10 | e3391Figure 3. In the human gut epithelial cell line Caco2, ATG16L1*300A is impaired in its ability to mediate anti-Salmonella autophagy.
(A) Caco2 cells were transduced with lentiviruses expressing non-targeting shRNA (control-shRNA) or ATG16L1-targeting shRNA (ATG16L1-shRNA).
Protein levels of endogenous ATG16L1 were detected in stably transduced cells by immunoprecipitation with anti-ATG16L1-02 antibody and Western
blot analysis using anti-ATG16L1-01 antibody (inset). The generated CaCo2 cell lines were nucleofected with both GFP-LC3 and either control (vector),
ATG16L1*300T or *300A expression constructs, as indicated. 48 h. after nucleofection cells were infected with S. Typhimurium for one hour and fixed.
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human ATG5 via its very N-terminus. (A) Schematic view of ATG16L1 expression constructs used in this manuscript. Amongst a number of
predicted isoforms, isoform 1 (Iso1) and isoform 2 (Iso2) of human ATG16L1 reflect homologues of mouse Apg16L isoforms b and a, respectively, and
are the most prominently known isoforms in humans. ATG16L1 Iso1 represents the longest human isoform and encodes for 607 amino acids with a
predicted coiled coil domain (amino acids 78–230, CC) and seven WD domains (amino acids 320–359, 364–403, 406–445, 447–484, 486–525, 532–573,
575–607, respectively, WD). Amino acid position 300 can be encoded by threonine or alanine (T/A), and individuals carrying alleles coding for alanine
(ATG16L1*300A) show a significantly increased risk for the development of CD. Iso2 lacks a stretch of 19 amino acids (amino acids 266–284 of Iso1)
resulting in a shorter 588 amino acid protein. For mutational studies, three truncated expression constructs of Iso1 have been generated encoding
amino acids 85–607 (DN), amino acids 1–341 (DWD) and amino acids 286–607 (WD), respectively. (B and C) HEK293T cells were co-transfected with
FLAG-tagged expression constructs of ATG16L1 (as shown in Fig. 4A) and MYC-tagged ATG16L1 Isoform 1 (B) or HA-tagged ATG5 (C), respectively.
40 h. post-transfection cells were harvested and lysed. While 10% of each lysate served as input-control, the remaining lysate was incubated with
goat anti-mouse beads and anti-FLAG-antibody overnight at 4uC to immunoprecipitate (IP) FLAG-ATG16L1 constructs. Over-expressed (input) and co-
precipitated MYC-tagged ATG16L1 Isoform 1 were determined by Western blotting using an anti-MYC antibody (Fig. 4B); ATG5 was detected using
anti-HA-antibody (Fig. 4C). Please note that under the conditions used only the monomeric (not conjugated to ATG12) form of ATG5 was expressed
in significant amounts, in addition ATG5 protein levels appear elevated/stabilized upon binding to ATG16L1. HC: heavy chain. Empty: vector
encoding the corresponding tag only.
doi:10.1371/journal.pone.0003391.g004
The percentage of GFP-LC3-positive bacteria and P values were determined as described in Fig. 2A. (B) Representative confocal optical sections of
infected ATG16L1-deficient and ATG16L1 allele-specific resconstituted Caco2 cells. GFP-LC3 (green in merge), SL1344 (red in merge) and actin (bluei n
merge) are shown, scale bars represent 10 mm. Note the lack of GFP-LC3-marked membranes around internalized bacteria in knock-down cells (top
row), recovery of autophagy in ATG16L1*300T-reconstituted cells (middle row) and partial recovery in *300A-reconstituted cells (bottom row).
doi:10.1371/journal.pone.0003391.g003
Impaired Autophagy in Crohn’s
PLoS ONE | www.plosone.org 6 October 2008 | Volume 3 | Issue 10 | e3391reduced. Therefore, we suggest that the ATG5/ATG16L1
interaction influences the turnover rate of ATG5 and may serve
to regulate the rate of autophagy.
Next, we examined whether ATG16L1*300T and the coding
variant *300A differ in their capacities to form ATG16L1
homodimers and to bind and stabilize monomeric ATG5.
FLAG-tagged ATG16L1*300T or *300A were co-expressed with
HA-tagged ATG5 or MYC-tagged ATG16L1*300T or *300A.
Co-precipitation assays were performed as before, using FLAG
antibody for immunoprecipitation followed by Western blotting
with MYC- or HA-antibody to detect co-precipitated proteins.
In these co-immunoprecipitation assays, we were not able to
detect any significant difference between ATG16L1*300T and
*300A with regard to ATG16L1 dimerisation, ATG5 binding or
the stabilization of monomeric ATG5 (Fig. 5A and B). These
observations argue against a defect in classical autophagy
mediated by the ATG16L1*300A variant, since the key features
of ATG16L1 (binding of ATG5 and other ATG16L1 moieties)
needed to form the ATG16L1/ATG5/ATG12 complex are not
affected by the ATG16L1*300A variant.
The ATG16L1*300T and *300A coding variants are both
fully competent in mediating basal autophagy
To test whether ATG16L1*300A might affect the overall rate of
basal autophagy, we applied our functional knock-down/recon-
stitution system using untagged ATG16L1*300T and *300A,
respectively. We co-transfected HeLa cells with control siRNA or
siRNA directed against ATG16L1 and either empty vector or
ATG16L1 variants, followed by treatment with ammonium
chloride to block turnover of the autophagy marker LC3 in
autolysosomes. Strikingly, expression of either ATG16L1 variant
was sufficient to reconstitute autophagosome formation in the
absence of endogenous ATG16L1 (Fig. 6). These findings indicate
that the ATG16L1*300A variant is unaffected in its ability to
mediate basal autophagy. In addition, the recently reported
inhibition of autophagy seen upon over-expression of N-terminal
tagged ATG16L1 in the presence of endogenous ATG16L1 does
not seem to be shared by untagged ATG16L1 constructs (Fig. 6),
supporting accuracy of data observed within our experimental
assay conditions.
Discussion
The strong association with CD of two autophagy-associated
genes (ATG16L1 and IRGM), both with known roles in anti-
bacterial autophagy, is strong evidence for a causal role for altered
autophagy in the pathogenesis of CD. Given the essential role for
autophagy in development and metabolism, it is difficult to
conceive that CD-associated mutations would have marked
systemic effects upon overall levels of autophagy. Our under-
standing of autophagy has been largely informed by the
characterization of the yeast system, although increasing interest
in mammalian autophagy has driven a series of recent discoveries
[6,18,19]. Despite their common essential role for autophagy in
yeast and mammalian cells [11,17], ATG16(L1) proteins from
yeast and mammals show notable differences. Mammalian
ATG16L1 proteins share the core domains of the yeast ATG16
molecule, but possess additional WD-repeat domains [10,16,20].
Therefore, we hypothesized that the WD-repeats of ATG16L1
display additional protein-protein interactions over the yeast
molecule, and these interactions may be necessary for specialized
forms of autophagy, such as anti-bacterial autophagy. The
positioning of the CD-associated coding SNP (ATG16L1*300A
or T300A) close to the WD allows the possibility that the CD-
associated variant exhibits a phenotype in anti-bacterial autoph-
agy. In addition, the role of the IRGM protein appears to be most
prominent in anti-bacterial autophagy, further suggesting that
anti-bacterial autophagy contributes to the pathogenesis of CD.
In order to investigate the role of ATG16L1 variants in
autophagy, we applied a knock-down and reconstitution system
using RNAi to ablate endogenous ATG16L1, while reconstituting
ATG16L1 expression with RNAi-resistant cDNA constructs. We
suggest that this approach is likely to reveal subtle and
intermediate phenotypes likely to be characteristic of commonly-
Figure 5. The formation of ATG16L1-homodimers and
ATG16L1-ATG5-heterodimers is not affected by the *300A/T
polymorphism. (A) HEK293T cells were co-transfected with FLAG and
MYC-tagged ATG16L1*300A or *300T, as indicated. FLAG-tagged
proteins were immunoprecipitated using anti-FLAG antibody. Both
the inputs of MYC-ATG16L1 and co-precipitated MYC-ATG16L1 are
shown. (B) HEK293T cells were co-transfected with FLAG-tagged
ATG16L1*300A or *300T and HA-tagged ATG5, respectively, as
indicated. Shown are inputs, as well as immunoprecipitated FLAG-
ATG16L1 and co-precipitated monomeric HA-ATG5. Under the condi-
tions used, only the monomeric (not conjugated to ATG12) form of
ATG5 was expressed in significant amounts.
doi:10.1371/journal.pone.0003391.g005
Figure 6. Overall levels of basal autophagy are not affected by
the ATG16L1*300A polymorphism. HeLa cells were transfected as
described in Fig. 2A. 48 h. post-transfection 50 mM ammonium chloride
(NH4Cl) was added for 2 h. where indicated. Protein levels of LC3 and
actin were detected by Western blotting using anti-LC3B and anti-actin
antibodies, respectively.
doi:10.1371/journal.pone.0003391.g006
Impaired Autophagy in Crohn’s
PLoS ONE | www.plosone.org 7 October 2008 | Volume 3 | Issue 10 | e3391carried genetic variants. Additionally, in accordance with
observations for murine ATG16L1 [14], we observed an
inhibitory, or at least functionally compromised, effect mediated
by N-terminal tagged human ATG16L1. While we believe that
this is in part due to an abnormally high stability of N-terminal
tagged proteins (P. Kuballa, unpublished data), we have been able
to successfully circumvent inhibition by using ATG16L1 con-
structs carrying no tag, regardless of the exact mechanism of
inhibition/dysfunction related to N-terminal tagged ATG16L1.
Using this system, we were able to demonstrate that basal levels
of autophagy are unaffected by the presence of the CD-associated
ATG16L1 mutation. Indeed, the interactions of ATG16L1 with
other ATG16L1 moieties as well with ATG5 appear to be
unaffected by the ATG16L1*300A/T polymorphism. This is
perhaps not entirely surprising, since we were able to demonstrate
that regions of ATG16L1 essential for interactions with ATG5 and
other ATG16L1 moieties lie upstream of amino acid 300, which is
affected by the identified functional SNP.
However, we were able to observe a marked decrease in the
efficiency of anti-bacterial autophagy in both HeLa and CaCo2
cells expressing the CD-associated ATG16L1*300A allele com-
pared to cells expressing the ATG16L1*300T allele, suggesting
that handling of intracellular pathogens or internalized antigens
might be altered in patients possessing the ATG16L1*300A allele.
In addition, impairment of anti-bacterial autophagy correlated
with a decrease in ATG16L1*300A expression levels in HeLa
cells, while under the conditions used for functional assays
(nucleofection of 5610
5 cells) expression levels of ATG16L1 were
below the detection limit in the number of Caco2 cells, which
survived the nucleofection procedure (Please note, that expression
levels shown in Fig. 3A, inset have been derived from 10 cm
plates). Thus, we are unable to definitively state whether the
decrease in ATG16L1*300A protein stability reflects the mecha-
nism of impairment, or if deficient or excessive protein-protein
interactions of *300A compared to *300T are responsible for
impaired capture of bacteria within autophagosomes.
However, whilst Salmonellae are not the causative agents of CD,
nor present in the majority of patients, we anticipate that many of
the cellular autophagy mechanisms necessary for microbe
recognition and processing are shared for different intracellular
pathogens. Thus, we believe that patients with the AT-
G16L1*300A allele are likely to be fully competent for the
homeostatic functions of autophagy, yet may exhibit altered
responses to bacterial components and infection in the gut milieu,
where antigen burden is high. Whilst one advantage of the cell
culture system used in this study is reflected by a direct comparison
of ATG16L1 coding variants within an otherwise identical
genomic background, we are currently seeking to confirm our
results in cells derived from patients carrying the ATG16L1*300T
or ATG16L1*300A alleles. However, a critical control, rescue of
phenotypes in ATG16L1*300A-expressing cells from patients by
exogenous expression of ATG16L1*300T, is likely to be
challenging due to technical limitations.
Since autophagy is involved in the cross-presentation of
intracellular antigens via MHC class II, it will be of interest to
observe whether antigen presentation is modified in the context of
ATG16L1*300A compared to ATG16L1*300T expressing cells
[21]. This may be of particular importance in the gut
microenvironment, where continual sampling, presentation and
response to luminal antigens are performed by M cells, Paneth
cells and dendrites extending between epithelial cells. Our
observation that the ATG16L1*300A protein may exhibit altered
stability under conditions of high microbial load also suggests that
defects are most likely to become functionally relevant under such
conditions. In addition, it is possible that modifications of
autophagy may alter the host adaptive responses to self antigens
via changes in cross-presentation of endogenous peptides [21].
Together, our observations suggest that the net effect of
ATG16L1 coding variation will depend upon the balance between
the high microbial load in the gut and the ability of autophagy to
mediate defense against invading pathogens and internalized self-
and non-self antigens.
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